Our experimental results confirmed that this therapeutic strategy can be synergistic with multiple anti-tumor mechanisms to exert effective anti-tumor activities, showing a significant inhibitory effect against the growth of HCC xenografts, especially for Survivin positive HCC. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.